These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30796023)

  • 1. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.
    Pemmaraju N; Kantarjian H; Nastoupil L; Dupuis M; Zhou L; Pierce S; Patel KP; Masarova L; Cortes J; Verstovsek S
    Blood; 2019 May; 133(21):2348-2351. PubMed ID: 30796023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms.
    McLornan DP; Harrison CN
    Br J Haematol; 2020 Oct; 191(1):21-36. PubMed ID: 32167592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
    Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
    J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
    Patterson-Fortin J; Moliterno AR
    Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical modeling reveals alternative JAK inhibitor treatment in myeloproliferative neoplasms.
    Shank K; Dunbar A; Koppikar P; Kleppe M; Teruya-Feldstein J; Csete I; Bhagwat N; Keller M; Kilpivaara O; Michor F; Levine RL; de Vargas Roditi L
    Haematologica; 2020 Mar; 105(3):e91-e94. PubMed ID: 31413098
    [No Abstract]   [Full Text] [Related]  

  • 6. Germline polymorphisms and the risk of therapy-related myeloid neoplasms.
    Takahashi K
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):24-30. PubMed ID: 30927971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
    Winter PS; Sarosiek KA; Lin KH; Meggendorfer M; Schnittger S; Letai A; Wood KC
    Sci Signal; 2014 Dec; 7(357):ra122. PubMed ID: 25538080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of B-cell lymphoma in MPN patients treated with JAK1/2 inhibitors: Contradictory results?
    Costanza M; Spertini O; Blum S
    Leuk Res; 2020 Mar; 90():106313. PubMed ID: 32058175
    [No Abstract]   [Full Text] [Related]  

  • 9. Preface.
    Verstovsek S
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):81-2. PubMed ID: 25189719
    [No Abstract]   [Full Text] [Related]  

  • 10. Myeloproliferative Neoplasms: Translating New Discoveries Into Better Outcomes, Better Quality of Life.
    Padrnos L; Mesa RA
    Oncology (Williston Park); 2017 Jul; 31(7):521-9. PubMed ID: 28712096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms.
    Rampal R; Levine RL
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):83-93. PubMed ID: 25189720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on the epigenome in the myeloproliferative neoplasms.
    Kim E; Abdel-Wahab O
    Hematology Am Soc Hematol Educ Program; 2013; 2013():538-44. PubMed ID: 24319229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic analysis of myeloproliferative neoplasms in chronic and acute phases.
    Courtier F; Carbuccia N; Garnier S; Guille A; Adélaïde J; Cervera N; Gelsi-Boyer V; Mozziconacci MJ; Rey J; Vey N; Chaffanet M; Birnbaum D; Murati A
    Haematologica; 2017 Jan; 102(1):e11-e14. PubMed ID: 27742771
    [No Abstract]   [Full Text] [Related]  

  • 14. Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.
    Loscocco GG; Mannelli F; Guglielmelli P; Paoli C; Marone I; Cucci R; Coltro G; Sordi B; Albano F; Breccia M; De Stefano V; Finazzi G; Iurlo A; Martino B; Palandri F; Passamonti F; Siragusa S; Mannelli L; Fantoni D; Fazi P; Amadori S; Vignetti M; Barbui T; Vannucchi AM
    Am J Hematol; 2019 Sep; 94(9):E239-E242. PubMed ID: 31179561
    [No Abstract]   [Full Text] [Related]  

  • 15. Atrial fibrillation and MPNs.
    Alvarez-Larrán A
    Ann Hematol; 2018 Apr; 97(4):743. PubMed ID: 29335767
    [No Abstract]   [Full Text] [Related]  

  • 16. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloproliferative and lymphoproliferative disorders: State of the art.
    Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
    Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].
    Kubuki Y; Hidaka T; Shimoda K
    Rinsho Ketsueki; 2015 Oct; 56(10):1996-2004. PubMed ID: 26458438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
    Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
    Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
    [No Abstract]   [Full Text] [Related]  

  • 20. Preface.
    Michaelis LC
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):1-2. PubMed ID: 30927968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.